A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance
Qiyao Zheng(Sun Yat-sen University), Xiaolei Zhang(Jiangsu Province Hospital), Jianshan Mo(Sun Yat-sen University), Yuanxiang Wang(Sun Yat-sen University), Wenhao Hu(Sun Yat-sen University), Peiqing Liu(General Administration of Quality Supervision, Inspection and Quarantine), Shumin Ouyang(Dongguan People’s Hospital), Yi Zhang(Tianjin Medical University General Hospital), Hui Dong(Nanjing University of Chinese Medicine), Kai Zhu(Taishan Medical University), Jie Huang(Sun Yat-sen University), Xinming Qu(Changchun University of Chinese Medicine), Shuo Shi(Tongji University)
Cited by 110
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k